Patient characteristics (N = 38)
| Sex, n (%) | |
| Male | 15 (39) |
| Female | 23 (61) |
| Age, y | |
| Median | 34 |
| Range | 25-62 |
| Race, n (%) | |
| White | 34 (89) |
| Black | 2 (5) |
| Hispanic | 1 (3) |
| Asian | 1 (3) |
| Histology, n (%) | |
| Nodular sclerosis | 30 (79) |
| Mixed cellularity | 4 (10.5) |
| Classical, not-otherwise-specified | 4 (10.5) |
| Disease status, n (%) | |
| Relapsed | 17 (45) |
| Refractory | 21 (55) |
| B symptoms, n (%) | |
| Yes | 13 (34) |
| No | 25 (66%) |
| Performance status, n (%) | |
| 0 | 22 (58) |
| 1 | 13 (34) |
| 2 | 3 (8) |
| Prior chemotherapy regimens, n | |
| Median | 4 |
| Range | 2-9 |
| Prior radiation therapy, n (%) | |
| Yes | 24 (63) |
| No | 14 (37) |
| Prior stem cell transplantation, n (%) | |
| Yes | 33 (87) |
| No | 5 (13) |
| Prior stem cell transplantation type, n (%) | |
| Autologous | 29 (76) |
| Syngeneic | 1 (3) |
| Autologous and allogeneic | 3 (8) |
| Time from last therapy to enrollment, mo | |
| Median | 3.5 |
| Range | 1-66 |
| Sex, n (%) | |
| Male | 15 (39) |
| Female | 23 (61) |
| Age, y | |
| Median | 34 |
| Range | 25-62 |
| Race, n (%) | |
| White | 34 (89) |
| Black | 2 (5) |
| Hispanic | 1 (3) |
| Asian | 1 (3) |
| Histology, n (%) | |
| Nodular sclerosis | 30 (79) |
| Mixed cellularity | 4 (10.5) |
| Classical, not-otherwise-specified | 4 (10.5) |
| Disease status, n (%) | |
| Relapsed | 17 (45) |
| Refractory | 21 (55) |
| B symptoms, n (%) | |
| Yes | 13 (34) |
| No | 25 (66%) |
| Performance status, n (%) | |
| 0 | 22 (58) |
| 1 | 13 (34) |
| 2 | 3 (8) |
| Prior chemotherapy regimens, n | |
| Median | 4 |
| Range | 2-9 |
| Prior radiation therapy, n (%) | |
| Yes | 24 (63) |
| No | 14 (37) |
| Prior stem cell transplantation, n (%) | |
| Yes | 33 (87) |
| No | 5 (13) |
| Prior stem cell transplantation type, n (%) | |
| Autologous | 29 (76) |
| Syngeneic | 1 (3) |
| Autologous and allogeneic | 3 (8) |
| Time from last therapy to enrollment, mo | |
| Median | 3.5 |
| Range | 1-66 |